Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 162

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 162
---
Payments of deferred offering costs— (281)— Payments on revenue interest liability— (195,577)(5,552)Net cash provided by financing activities17,699 336,600 109,087 Effect of exchange rate on cash, cash equivalents and restricted cash(1,297)(133)12 Net (decrease) increase in cash, cash equivalents and restricted cash(63,398)158,323 (3,337)Cash, cash equivalents and restricted cash equivalents at beginning of period286,326 128,003 131,340 Cash, cash equivalents and restricted cash at end of period$222,928 $286,326 $128,003 Supplemental disclosure of cash flow information:Operating cash flows paid for operating lease$1,274 $1,079 $911 Cash paid for interest$12,650 $6,817 $— Cash paid for income taxes$1,004 $125 $— Non-cash operating, investing and financing activities:Accrued milestone payments classified as intangible assets, net$— $— $15,000 Right-of-use assets obtained in exchange for lease liabilities$9,633 $473 $285 Decrease in ROU assets and lease liabilities due to lease modification$723 $— $— Stock-based compensation capitalized to inventory$1,122 $822 $441 Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities$— $5,188 $— Contingent Milestone and Indemnification Holdback liabilities for common stock issuance in exchange for acquired intangible assets$— $— $5,431 Issuance of common stock in exchange for acquired intangible$— $— $15,585 Deferred tax liability incurred from acquired intangible$— $— $6,580 

The accompanying notes are an integral part of these consolidated financial statements.

109